There are about 53 million surgeries performed in the U.S. each year that require drugs for post-operative pain, and over half of these patients still experience inadequate pain relief
The most common causes of chronic pain are musculoskeletal problems and inflammatory conditions
Studies on the effects of cannabis have led to the discovery of an endogenous system of ligands involved in pain and inflammation
Discovery of compounds with new pharmacological properties at identified GPCR dimeric drug targets
Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics.
Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain.
This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications.
In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Professionals
Cara Therapeutics was formed in order to take advantage of new opportunities to develop safer, more effective analgesics.
Learn More...
Corporate Development & Media
Cara Therapeutics is a privately held company. Since incorporation in 2004, Cara has completed four rounds of equity financing.
Learn More...
Careers
At Cara, researchers will find a collaborative and dynamic environment where individual contributions and inventiveness are highly valued.
Learn More...
